140 related articles for article (PubMed ID: 8281618)
1. Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.
Houghton PJ; Cheshire PJ; Hallman JC; Gross JL; McRipley RJ; Sun JH; Behrens CH; Dexter DL; Houghton JA
Cancer Chemother Pharmacol; 1994; 33(4):265-72. PubMed ID: 8281618
[TBL] [Abstract][Full Text] [Related]
2. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Houghton PJ; Cheshire PJ; Myers L; Stewart CF; Synold TW; Houghton JA
Cancer Chemother Pharmacol; 1992; 31(3):229-39. PubMed ID: 1464161
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(1):45-52. PubMed ID: 7720175
[TBL] [Abstract][Full Text] [Related]
7. The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II.
Nitiss JL; Zhou J; Rose A; Hsiung Y; Gale KC; Osheroff N
Biochemistry; 1998 Mar; 37(9):3078-85. PubMed ID: 9485461
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma.
Houghton PJ; Houghton JA; Myers L; Cheshire P; Howbert JJ; Grindey GB
Cancer Chemother Pharmacol; 1989; 25(2):84-8. PubMed ID: 2598403
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ
Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
[TBL] [Abstract][Full Text] [Related]
11. Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units.
Cobb PW; Degen DR; Clark GM; Chen SF; Kuhn JG; Gross JL; Kirshenbaum MR; Sun JH; Burris HA; Von Hoff DD
J Natl Cancer Inst; 1994 Oct; 86(19):1462-5. PubMed ID: 8089865
[TBL] [Abstract][Full Text] [Related]
12. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
Friedman HS; Dolan ME; Kaufmann SH; Colvin OM; Griffith OW; Moschel RC; Schold SC; Bigner DD; Ali-Osman F
Cancer Res; 1994 Jul; 54(13):3487-93. PubMed ID: 8012971
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of sulofenur and a second generation diarylsulfonylurea, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea (LY295501), against colon adenocarcinoma xenografts.
Houghton PJ; Cheshire PJ; Myers L; Lutz L; Toth J; Grindey GB; Houghton JA
Anticancer Drugs; 1995 Apr; 6(2):317-23. PubMed ID: 7795279
[TBL] [Abstract][Full Text] [Related]
14. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of DMP 840 against mouse and human solid tumor models.
LoRusso P; Demchik L; Dan M; Polin L; Gross JL; Corbett TH
Invest New Drugs; 1995; 13(3):195-203. PubMed ID: 8729946
[TBL] [Abstract][Full Text] [Related]
16. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
[TBL] [Abstract][Full Text] [Related]
17. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
Zamboni WC; Stewart CF; Thompson J; Santana VM; Cheshire PJ; Richmond LB; Luo X; Poquette C; Houghton JA; Houghton PJ
J Natl Cancer Inst; 1998 Apr; 90(7):505-11. PubMed ID: 9539245
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of DMP 840 in pediatric patients with refractory solid tumors.
Thompson J; Pratt CB; Stewart CF; Avery L; Bowman L; Zamboni WC; Pappo A
Invest New Drugs; 1998; 16(1):45-9. PubMed ID: 9740543
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard.
Horton JK; Houghton PJ; Houghton JA
Cancer Res; 1987 Dec; 47(23):6288-93. PubMed ID: 2890432
[TBL] [Abstract][Full Text] [Related]
20. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma.
Houghton JA; Cook RL; Lutz PJ; Houghton PJ
Cancer Treat Rep; 1985 Jan; 69(1):91-6. PubMed ID: 3967262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
